MSI

SBA Administrator Guzman Announces 17 New Women’s Business Centers

Retrieved on: 
Friday, March 29, 2024
Financial management, WBC, White blood cell, SBA, Master, MSI, Small business, Mentorship, Commerce, Male, Central business district, Senior counsel, Marketing, Human, Casino

“Under the Biden-Harris Administration, we have seen a historic Small Business Boom, with women, especially women of color, filing new business applications at double the rates of men,” said Administrator Guzman.

Key Points: 
  • “Under the Biden-Harris Administration, we have seen a historic Small Business Boom, with women, especially women of color, filing new business applications at double the rates of men,” said Administrator Guzman.
  • “The SBA’s expanding network of Women's Business Centers is meeting these new and established businesses where they are with resources to help them get funding to grow, create jobs, and strengthen our economy.
  • Through the SBA’s Office of Women’s Business Ownership (OWBO) , the 17 new WBCs – including 13 hosted by MSIs – will help diverse entrepreneurs pivot, grow, and navigate SBA resources they can use to ensure their businesses thrive.
  • “Through WBCs, the SBA provides practical help to women working hard to build successful businesses of their own,” said Christina Hale, Assistant Administrator for the Office of Women's Business Ownership .

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Retrieved on: 
Tuesday, April 9, 2024
Research, Clinical Trials, Biometrics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer, Doctor, MSI-H, Metastasis, Communication, Immunotherapy, Colorectal cancer, Patient, MSI, STC, Team, Doctor of Philosophy, Master of Science, MSS, Neoplasm, Vaccine

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Key Points: 
  • This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
  • Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
  • STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors.
  • Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured.

Motorola Solutions Presents Enterprise Security Innovation and Integration at ISC West

Retrieved on: 
Monday, April 8, 2024
Software, Mobile, Wireless, Networks, Hardware, Data Management, Other Construction & Property, Technology, Artificial Intelligence, Construction & Property, Security, Audio, Video, Building Systems, Temperature, Pelco, HALO, School, Humidity, Hospital, MSI, AI, Anomaly, Mercury, Orchestration, Radio, Firearm, DMS, Motorola Solutions, Safety

Motorola Solutions (NYSE: MSI) will demonstrate at ISC West new capabilities and flexible integrations across its safety and security ecosystem to help protect people, property and places.

Key Points: 
  • Motorola Solutions (NYSE: MSI) will demonstrate at ISC West new capabilities and flexible integrations across its safety and security ecosystem to help protect people, property and places.
  • Our flexible solutions enable enterprises of all types and sizes to view and manage their security operations from anywhere, 24/7."
  • Motorola Solutions will showcase at ISC West new additions to its cloud-managed and on-premise solutions that improve threat detection and simplify security operations for schools, hospitals, stadiums and other enterprises around the world.
  • Attendees can learn how Motorola Solutions is solving for safer communities, schools and businesses at ISC West in Las Vegas, April 10-12.

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024
ACT, Gene, Biotechnology, Acceleration, LOH, CDX, Risk, Patient, NGS, Biomarker, Research, MSI, DNA, Cancer, Spacecraft, AACR, MRD, Recurrence, FDA, Health, Plasma, Neoplasm, Medicine, Pharmaceutical industry

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Health Technology, Genetics, Other Science, Research, Science, Genomics, IHC, Methylation, Partnership, Laser, TMB, NGS, MSI, DNA, Biomarker, Cancer, Hydrofluoroolefin, Biology, Medicine, Imperial College London, AACR, Microsatellite instability, Neoplasm, Therapy, Agilent Technologies, Liquid biopsy, Machine learning, RNA-Seq, University of Oxford, CMO, Medical imaging

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .
  • Agilent Avida - Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample.
  • Agilent SureSelect Cancer Custom panels - Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays.
  • AACR attendees can also explore multiple Agilent research posters and over 50 additional customer posters highlighting Agilent instruments and solutions.

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Tempus, Survival, Colorectal cancer, Patient, RNA, MSI, FOLFIRINOX, PDAC, Medicine, Section 42, News, AACR, Microsatellite instability, Therapy, Cancer

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
  • Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
  • A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
  • Details of the AACR presentations are as follows:
    Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
    The posters will be accessible under the News & Events section of the Company’s website following the conference.

Austrian Ministry of the Interior chooses Motorola Solutions Body Cameras to Modernize Nationwide Front-line Policing

Retrieved on: 
Wednesday, March 20, 2024
Data Management, Technology, Law Enforcement, Emergency Services, Other Policy Issues, Security, Software, Other Defense, Defense, Public Policy, Government, Mobile, Wireless, Hardware, Interior, MSI, TETRA, Tetraethyl pyrophosphate, Safety, Motorola Solutions, Multimedia, Ministry, Police

Motorola Solutions (NYSE: MSI) today announced its deployment of 4,000 VB400 body cameras to police forces in Austria.

Key Points: 
  • Motorola Solutions (NYSE: MSI) today announced its deployment of 4,000 VB400 body cameras to police forces in Austria.
  • The nationwide rollout will help front-line teams to de-escalate potentially dangerous situations, capture evidence during operations and improve safety and transparency in all interactions.
  • Motorola Solutions has been a trusted partner of public safety organizations in Austria for over 20 years.
  • All public safety organizations including police, fire brigades and emergency services rely on the reliable and secure Tetron network, which uses TETRA digital radio technology from Motorola Solutions.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Monday, March 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Abstract, NCI, FOLFIRI, Prostate cancer, Immunotherapy, Adenocarcinoma, Colorectal cancer, PDLIM2, Physician, Patient, Lung, Biomarker, MSI, Breast, Cancer, AI, Doctor of Philosophy, Special session, MD, Lung cancer, Medicine, MBA, FOLFOX, AACR, PIM, MSS, Booth, POA, MRD, Future, Prognosis, SSP, ANTXR1, Vaccine

IRVING, Texas, March 28, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 10 studies across eight tumor types at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, 2024, in San Diego, CA, at Booth Number 1105. Caris President, David Spetzler, MS, PhD, MBA, will lead an AACR Scientist ↔ Survivor Program® Special Session titled, "Very Early Cancer Detection Assays: The Future or Fantasy," on Tuesday, April 9, from 1:00 – 1:45 PM.

Key Points: 
  • Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers.
  • (Poster Number: 7037/4)
    Poster and abstract summaries highlighting the Caris research presented at AACR 2024 will be available onsite at Caris' Booth (# 1105).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.